Source-grounded facts extracted from SI-BONE, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SI-BONE, Inc. shareholders approved Advisory vote to approve executive compensation.
“The compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved on an advisory basis. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 33,265,992 2,579,849 17,463 3,041,727”
SI-BONE, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 38,876,920 27,588 523 0”
SI-BONE, Inc. shareholders approved Election of Directors at the 2026-12-31 meeting.
“The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; (b) for or against, as well as abstentions, for the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; and (c) for or against, as well as abstentions, for the advisory vote to approve executive compensation.”
SI-BONE, Inc. amended Third Amendment to Lease with BIXBY SPE FINANCE 11, LLC valued at $43,696 per month (effective 2026-06-05).
“On June 5, 2026, SI-BONE, Inc. (the “ Company ”) and BIXBY SPE FINANCE 11, LLC (“ Landlord ”) entered into the Third Amendment to Lease (the “ Third Lease Amendment ”) to the Office Lease Agreement”
SI-BONE, Inc. reported quarter ended March 31, 2026 results: revenue $52.6 million, net income $4.3 million, EPS $0.10 per diluted share. Guidance raised.
“physician engagement and ~440% improvement in adjusted EBITDA First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $52.6 million, representing growth of 11.2% • U.S. revenue of $49.3 million, representing growth of 10.0% • Gross margin of 79.8% • Net loss of $4.3 million, representing an improvement of”
SI-BONE, Inc. entered into Lease with Orchard Commons, LLC (effective 2026-02-20).
“On February 20, 2026, SI-BONE, Inc. (the “Company”) and Orchard Commons, LLC (the “Landlord”) entered into a lease agreement (the “Lease”), pursuant to which the Company will lease approximately 50,485 square feet of space located at 88 West Plumeria Drive, San Jose, California 95134 (the “Premises”).”
Daniel Wolf was elected as Director at SI-BONE, Inc..
“On August 4, 2024, the Company’s board of directors (“Board”) elected Daniel Wolf to serve as a director of the Company effective August 5, 2024, until his successor is elected and qualified, or sooner in the event of his death, resignation or removal.”
SI-BONE, Inc. reported the quarter ended March 31, 2024 results: revenue $37.9 million, net income $10.9 million, or $0.27 per diluted share. Guidance raised.
“reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $37.9 million, representing growth of ~16% • U.S. revenue of $35.4 million, representing growth of ~16% • Gross margin of ~79% • Over 1,100 U.S. active physicians, representing an increase of”
SI-BONE, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On February 26, 2024, SI-BONE, Inc. (the "Company") issued a press release (the “Press Release”) announcing results for the quarter and year ended December 31, 2023.”
SI-BONE, Inc. reported the fiscal year ended December 31, 2023 results: revenue $138.5-138.7 million.
“Worldwide revenue expected to be in the range of $138.5-138.7 million, representing growth of approximately 30% compared to the prior year period”
SI-BONE, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $38.5-$38.7 million.
“Worldwide revenue expected to be in the range of $38.5-$38.7 million, representing growth of approximately 21% compared to the prior year period”
SI-BONE, Inc. reported the quarter ended September 30, 2023 results: revenue $34.0 million, net income $10.0 million, or $0.25 per diluted share, EPS $0.25 per diluted share. Guidance raised.
“disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2023. Recent Financial Highlights • Record worldwide revenue of $34.0 million for the third quarter 2023, representing approximately 29% growth over the corresponding period in 2022 • Record U.S. revenue of $32.3 million for the third quarter 2023,”
SI-BONE, Inc.: Adopted Second Amended and Restated Bylaws to implement Universal Proxy Rules and make technical changes (effective 2023-09-19).
“On September 19, 2023, in connection with the adoption of Rule 14a-19 by the U.S. Securities and Exchange Commission (the "Universal Proxy Rules"), the Board of Directors (the “Board”) of SI-BONE, Inc. (the “Company”) adopted and approved the Company’s Second Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), which became effective upon approval.”
SI-BONE, Inc. reported the quarter ended June 30, 2023 results: revenue $33.3 million, net income $11.2 million, or $0.30 per diluted share, EPS $0.30 per diluted share. Guidance raised.
“musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2023. Recent Highlights • Record worldwide revenue of $33.3 million for the second quarter 2023, representing approximately 30% growth over the corresponding period in 2022 • Record U.S. revenue of $31.2 million for the second quarter 2023,”
SI-BONE, Inc. shareholders approved Advisory vote to approve executive compensation as disclosed in the Proxy Statement at the 2023-06-09 meeting.
“Proposal 3: The compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved on an advisory basis.”
SI-BONE, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-09 meeting.
“Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.”
SI-BONE, Inc. shareholders approved Election of three directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-06-09 meeting.
“Proposal 1: Each of the three directors proposed by the Company for election was elected by the following votes to serve until SI-BO NE’s 2026 Ann ual Meeting of Stockholders, or until his respective successor has been elected and qualified.”
SI-BONE, Inc. reported fiscal year 2023 results: revenue $128 million to $131 million. Guidance raised.
“SI-BONE is updating its 2023 worldwide revenue guidance to be in the range of $128 million to $131 million, implying growth of approximately 20% to 23%.”
SI-BONE, Inc. reported the quarter ended March 31, 2023 results: revenue $32.7 million.
“musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2023. Recent Highlights • Record world wide revenue of $32.7 million for the first quarter 2023, representing approximately 46% increase over the corresponding period in 2022 • Record U.S. revenue of $30.5 million for the first quarter 2023,”
SI-BONE, Inc. reported fiscal year 2023 results: revenue approximately $124 million to $127 million. Guidance initiated.
“SI-BONE continues to experience demand momentum but remains cognizant of the early phase of re-acceleration of the U.S. business and the pace of international recovery. Considering these factors, SI-BONE expects 2023 worldwide revenue of approximately $124 million to $127 million, representing growth of approximately 17% to 19% compared to fiscal year 2022. SI-BONE also anticipates that gross margin will be approximately 80% for fiscal year 2023 and Adjusted EBITDA loss will continue to improve year over year in 2023.”
SI-BONE, Inc. reported the full year 2022 results: revenue $106.4 million, net income $61.3 million, EPS $1.79 per diluted share.
“Revenue was $106.4 million for 2022, a 18% increase from $90.2 million in 2021. U.S. revenue for 2022 was $98.8 million, a 19% increase from $82.7 million in 2021, primarily driven by growth of domestic case volumes. International revenue was $7.7 million in 2022 compared to $7.4 million in 2021 as overall volume growth was offset by unfavorable foreign exchange rates and challenges in select international markets. Gross margin was 85% for 2022, compared to 88% in 2021. In 2022, the gross margin was impacted by lower average selling prices driven by product mix, procedure mix, site of service mix, higher freight, as well as higher cost of new products and depreciation related to new product instrument tray costs. Operating expenses increased 14% to $150.3 million in 2022 compared to $131.4 million in 2021. The increase was driven by increases in headcount, sales commissions, research and development expenses, stock-based compensation expense and travel costs. Net loss was $61.3 million”
SI-BONE, Inc. reported the fourth quarter 2022 results: revenue $32.0 million, net income $11.2 million, EPS $0.32 per diluted share.
“Worldwide revenue was $32.0 million in the fourth quarter 2022, a 27% increase from $25.2 million in the prior year period. U.S. revenue for the fourth quarter 2022 was $30.0 million, an increase of 28% from $23.3 million in the prior year period primarily driven by growth of domestic case volumes. International revenue was $2.0 million in the fourth quarter 2022 compared to $1.9 million in the prior year period. International revenue growth was impacted by unfavorable foreign exchange rates and challenges in select international markets. Gross margin was 84% for the fourth quarter 2022, compared to 87% in the prior year period. Gross margin in the fourth quarter 2022 was impacted by lower average selling prices driven by procedure mix, product mix, site of service mix, higher freight, as well as higher cost of new products and depreciation related to new product instrument tray costs. Operating expenses increased 7% to $38.2 million in the fourth quarter 2022 compared to $35.8 million”
SI-BONE, Inc. reported full year 2022 results: revenue $106.1 - $106.3 million.
“Fiscal Year 2022 revenue of $106.1 - $106.3 million representing growth of approximately 18%”
SI-BONE, Inc. reported fourth quarter 2022 results: revenue $31.7 - $31.9 million.
“SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022 Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26%”
SI-BONE, Inc. incurred credit facility of $36.0 million term loan and up to $15.0 million revolving credit facility, plus uncommitted accordion term loan of up to with Silicon Valley Bank at Floating annual rate on Term Loan: greater of prime rate plus 0.5% or 6.75%; on maturing Term Loan matures December 1, 2027; Revolver matures July 6, 2025.
“On January 6, 2023, SI-BONE, Inc. (the “ Company ”) entered into a First Amendment to Loan and Security Agreement (the “ Amendment ”) with Silicon Valley Bank., a California corporation (“ SVB ”), which amends the Company's Loan and Security Agreement dated as of August 12, 2021, by and between the Company and SVB pursuant to which the Company had a term loan facility in an aggregate principal amount of $35.0 million (the “ Original Loan Agreement” and with the Amendment, collectively the “Amended Loan Agreement”) . Upon entry into the Amended Loan Agreement, the Company borrowed $36.0 million pursuant to a term loan (the " Term Loan "), which was substantially used to repay in full the $35.0 million term loan facility outstanding under the Original Loan Agreement and secured a revolving credit facility in an aggregate principal amount of up to $15.0 million (the " Revolver ").”
SI-BONE, Inc. amended First Amendment to Loan and Security Agreement with Silicon Valley Bank (SVB) valued at $36.0 million (effective 2023-01-06).
“On January 6, 2023, SI-BONE, Inc. (the “ Company ”) entered into a First Amendment to Loan and Security Agreement (the “ Amendment ”) with Silicon Valley Bank., a California corporation (“ SVB ”), which amends the Company's Loan and Security Agreement dated as of August 12, 2021”
SI-BONE, Inc. reported the quarter ended September 30, 2022 results: revenue $26.4 million, net income $14.2 million, EPS $0.41 per diluted share.
“musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Record world wide revenue of $26.4 million for the third quarter 2022, representing approximately 19% increase over the corresponding period in 2021 • Record U.S. revenue of $24.6 million for the third quarter 2022,”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.